Current and Emerging Therapies for Follicular Lymphoma: Solving Practice Challenges in Community-Based Interprofessional Care Teams
| Overview / Abstract: |
An indolent subtype of non-Hodgkin lymphoma, follicular lymphoma is characterized by eventual relapse of disease and the need for multiple lines of therapy, adding to the significant disease burden experienced by patients. Novel targeted agents in the relapsed/refractory setting have afforded new treatment options, but important clinical challenges exist, including optimal treatment sequencing, therapy evaluation and patient selection, transitions of care requirements, as well as toxicity management. In this 1-hour, online activity, lymphoma expert Jeremy Abramson, MD, shares his experience navigating these challenges as part of an interprofessional, multidisciplinary care team. |
|
Expiration |
Dec 22, 2024 |
|
Discipline(s) |
Pharmacy CPE, Physician CME |
|
Format |
Online, Webinar / Webcast / Video |
|
Credits / Hours |
1.0 |
|
Accreditation |
AAPA, ACPE, AMA, ANCC, CA-BRN |
|
Presenters / Authors / Faculty |
Jeremy S. Abramson, MD, MMSc |
|
Sponsors / Supporters / Grant Providers |
Supported by independent educational grants from Genentech, a member of the Roche Group, and Novartis Pharmaceuticals |
|
Keywords / Search Terms |
Annenberg Center for Health Sciences lymphoma, follicular lymphoma, indolent lymphoma, non-Hodgkin lymphoma Free CE CME |
|